Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2015, Article ID 952019, 3 pages
http://dx.doi.org/10.1155/2015/952019
Case Report

Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor

1Internal Medicine Residency Program, Florida Hospital, 2501 N. Orange Avenue, Suite 235, Orlando, FL 32804, USA
2Cancer Institute of Florida, Florida Hospital, 2501 N. Orange Avenue, Suite 235, Orlando, FL 32804, USA

Received 24 May 2015; Accepted 21 July 2015

Academic Editor: Carlo Capella

Copyright © 2015 Vladimir Pech et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Lawrence, B. I. Gustafsson, A. Chan, B. Svejda, M. Kidd, and I. M. Modlin, “The epidemiology of gastroenteropancreatic neuroendocrine tumors,” Endocrinology and Metabolism Clinics of North America, vol. 40, no. 1, pp. 1–18, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. B. I. Gustafsson, M. Kidd, A. Chan, M. V. Malfertheiner, and I. M. Modlin, “Bronchopulmonary neuroendocrine tumors,” Cancer, vol. 113, no. 1, pp. 5–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. R. Strosberg, A. Nasir, P. Hodul, and L. Kvols, “Biology and treatment of metastatic gastrointestinal neuroendocrine tumors,” Gastrointestinal Cancer Research, vol. 2, no. 3, pp. 113–125, 2008. View at Google Scholar
  4. J. C. Yao, M. H. Shah, T. Ito et al., “Everolimus for advanced pancreatic neuroendocrine tumors,” The New England Journal of Medicine, vol. 364, no. 6, pp. 514–523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Raymond, L. Dahan, J.-L. Raoul et al., “Sunitinib malate for the treatment of pancreatic neuroendocrine tumors,” The New England Journal of Medicine, vol. 364, no. 6, pp. 501–513, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. B. J. Lamont and S. Andrikopoulos, “Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?” Journal of Endocrinology, vol. 221, no. 1, pp. T43–T61, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. A. J. Scheen, “Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes,” Expert Opinion on Drug Safety, vol. 14, no. 4, pp. 505–524, 2015. View at Publisher · View at Google Scholar
  8. G. Larrinaga, L. Blanco, P. Errarte et al., “Altered peptidase activities in thyroid neoplasia and hyperplasia,” Disease Markers, vol. 35, no. 6, pp. 825–832, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Larrinaga, L. Blanco, B. Sanz et al., “The impact of peptidase activity on clear cell renal cell carcinoma survival,” The American Journal of Physiology—Renal Physiology, vol. 303, no. 12, pp. F1584–F1591, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Vangoitsenhoven, C. Mathieu, and B. Van Der Schueren, “GLP1 and cancer: friend or foe?” Endocrine-Related Cancer, vol. 19, no. 5, pp. F77–F88, 2012. View at Publisher · View at Google Scholar · View at Scopus